Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study (Q35595723)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 1, 2003

Language	Label	Description	Also known as
English	Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study	scientific article published on June 1, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study (English)

1 reference

Europe PubMed Central

9 August 2017

0 references

multicenter clinical trial

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rofecoxib Rheumatoid Arthritis Endoscopy Study Group

7

1 reference

Europe PubMed Central

9 August 2017

C. J. Hawkey

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

L. Laine

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

T. Simon

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

H. Quan

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

S. Shingo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

J. Evans

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

9 August 2017

full work available at URL

https://gut.bmj.com/content/gutjnl/52/6/820.full.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

https://europepmc.org/articles/PMC1773685

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

https://europepmc.org/articles/PMC1773685?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740337

1 January 2024

https://syndication.highwire.org/content/doi/10.1136/gut.52.6.820

1 reference

10.1136/GUT.52.6.820

https://api.crossref.org/works/10.1136/GUT.52.6.820

1 January 2024

1 reference

Europe PubMed Central

9 August 2017

52

1 reference

Europe PubMed Central

9 August 2017

6

1 reference

Europe PubMed Central

9 August 2017

820-826

1 reference

Europe PubMed Central

9 August 2017

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Gastrointestinal blood loss. Effect of aspirin, fenoprofen, and acetaminophen in rheumatoid arthritis as determined by sequential gastroscopy and radioactive fecal markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

12 July 2018

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

26 September 2018

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773685

26 September 2018

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Towards a better aspirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose famotidine for prevention of NSAID ulcers?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

https://pubmed.ncbi.nlm.nih.gov/12740337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.52.6.820

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35595723&oldid=2042038578"